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Background/aim: Calcitonin level in fine-needle aspirate washout fluid (Ct-FNA) was extensively studied for thyroid nodules and lymph
nodes (LN). However, the data was scarce for neck recurrences/metastases of medullary thyroid cancer (MTC). Thus, the diagnostic
accuracy of Ct-FNA and cytology in the detection of neck LN metastases of recurrent MTC cases were assessed.
Materials and methods: The database of MTC patients between 2010 and 2021 was retrospectively reviewed. A total of 32 patients
with recurrent MTC and suspicious LN who underwent FNA and Ct measurement from washout samples were included in this study.
Preoperative serum Ct (sCt), Ct-FNA, Ct-FNA/sCt ratio, cytology data were recorded for all participants.
Results: Median sCt of 32 patients and Ct-FNA washout fluid levels of operated suspicious 44 LNs were 723 (54–9000) pg/mL and
1800 (151–9500) pg/mL, respectively. The diagnostic accuracy of Ct-FNA washout fluid was greater than cytology (95.4% vs. 86%,
respectively). Using a cut-off level of >638.5 pg/mL, the Ct-FNA predicted the diagnosis of LN metastasis of recurrent MTC with a
sensitivity of 80% and specificity of 94.9%. Furthermore, using a cut-off level of >1.16, the Ct-FNA/sCt ratio well predicted the diagnosis
of LN metastasis of recurrent MTC with a sensitivity of 92.3% and specificity of 100%.
Conclusion: As Ct-FNA has greater diagnostic accuracy in our study, it would be complementary to cytology results to localize
metastatic LNs in recurrent MTC. Furthermore, for the first time, we demonstrated that the Ct-FNA/sCt ratio was a better predictor of
metastatic LNs in recurrent MTC than a particular cut-off for Ct-FNA alone.
Key words: Recurrent medullary thyroid cancer, fine needle aspiration cytology, calcitonin, washout sample

1. Introduction
Medullary thyroid carcinoma (MTC) is a neuroendocrine
malignancy, that originates from calcitonin (Ct) producing
parafollicular C-cells of the thyroid and accounts for 3%–
5% of all thyroid malignancies [1]. Metastasis to regional
lymph nodes (LN) may occur more often and earlier than
in differentiated thyroid cancers (DTC) [2]. Even if the
initial surgery is supposed to be adequate, the recurrence
rate remains up to 40%–66% [3]. MTC can metastasize
to the cervical LNs in 68%–80% of patients [4]. The
biochemical cure is achievable in 18.6% of reoperative
patients through the use of compartment-oriented LN
microdissection [3]. The optimal surgical management for
the persistent or recurrent disease remains controversial,
because of the long-term outcomes for these procedures.
The 5- and 10-year survival for medullary carcinomas are
65%–89% and 71%–87%, respectively [5] and it handles
up to 14% of thyroid-related deaths [6].

Serum Ct is a useful marker in diagnosis, differential
diagnosis, assessment of treatment, and follow-up of the
MTC [7,8]. But, the location of MTC in the thyroid gland
or cervical metastases cannot be achieved by serum Ct
measurements. Fine-needle aspiration cytology (FNAC)
represents the current diagnostic technique for the
identification of MTC neck LN metastases both before
and after thyroidectomy. However, the diagnostic accuracy
of FNAC (<50%) in diagnosing MTC is not as high as it
is for DTCs [9]. Ct measurement in the wash-out fluid of
FNA (Ct-FNA) to diagnose MTC, represents an additional
highly reliable marker, and it improves the sensitivity of the
diagnosis [10]. While there was no such a recommendation
before, the recent American Thyroid Association (ATA)
MTC guideline declared the usefulness of Ct-FNA when
FNA findings are inconclusive or suggestive of MTC [11].
Until now, many studies and metaanalyses have discussed
the utility of this method for thyroid nodules and LNs,
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but due to the rarity of the disease, a few studies have been
conducted for neck recurrences/metastases of MTC [1,12].
The purpose of this present study was to compare
the clinical usefulness of Ct-FNA versus cytology in the
identification of neck LN metastases in our recurrent cases
and select a ratio for Ct-FNA/sCt rather than Ct-FNA cutoff values for LN metastases for the first time.
2. Materials and methods
MTC patients (between January 2010 and January 2021)
were retrospectively analyzed. Clinical data were obtained
from medical records of Ankara University, Faculty of
Medicine, İbni Sina Hospital. Physical examination, reports
of neck ultrasonography (US), cytology results of USguided FNAC of suspicious LNs, and Ct-FNA results were
recorded. The participants signed the written informed
consent before the FNAC procedure. The study protocol
was in compliance with the principles outlined in the
Declaration of Helsinki and approved by the Institutional
Ethics Committee (İ11-712-20). Recurrent MTC was
defined as evidence of loco regional (either single/or a
group of LNs) or distant MTC in which the postoperative
sCt level was normal after initial surgery at least 6 months
[13]. Reoperations were done according to curative intent
or palliative intent.
2.1. Assessment of serum calcitonin
Blood samples were obtained from participants in the
morning, after 12 h of fasting, to measure serum Ct
and carcinoembryonic antigen (CEA) at preoperative
and postoperative period. None of the patients had
hyperparathyroidism, hepatic or renal insufficiency. None
of them were smokers or were using drugs that stimulate
Ct secretion.
Serum TSH, fT3, fT4 levels were assessed using a direct
chemiluminescence immunoassay (Siemens, ADVIA
Centaur XP ImmunoassaySystem, Tarrytown, NY, USA).
The Ct levels were measured with immunoradiometric
assay (IRMA) (Diasource Immunoassays S.A, catalog
number KIP0429, Belgium). Human CEA ELISA Kit
was used for the colorimetric detection method (Abcam,
catalog number ab99992, United Kingdom). Normal range
values for serum Ct are less than <10 pg/mL for both men
and women and CEA less than 3 ng/mL for nonsmokers
and less than 7 ng/mL for smokers, respectively.
2.2. Assessment of the neck and pathological lymph nodes
A group of experienced endocrinologists (M.F.E., S.G., R.E.,
M.Ş., and A.G.C.) performed the thyroid ultrasonography
by using a high-resolution Hitachi EUB 7000 HV machine
with a 6–13 MHz linear transducer, Tokyo, Japan. All
cervical LNs were identified and localized, and their
diameters were measured. Suspicious LNs were identified
according to ATA guidelines [14, 15] and submitted to
FNAC.
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2.3. Evaluation of FNAC and Ct-FNAC
Ultrasound-guided FNAC was performed with a 23
or 25-gauge needle and the aspirated material was
smeared directly on glass slides and air-dried smears
were stained with May-Grunwald-Giemsa (MGG) stain.
An experienced thyroid cytopathologist (K.C.), who
was unaware of Ct-FNAC results, made the cytological
examination. Cytology was reported as positive for
malignancy /consistent with MTC metastasis, negative for
malignancy/benign cytology and nondiagnostic cytology/
unsatisfactory for cytological evaluation.
A total of 44 suspicious LNs were aspirated for CtFNAC and FNAC. But because of the paucity of one of
the aspirated materials to be smeared to the slides, it had
not been sent to the cytology department, and it had been
rather used for wash-out sample.
After smearing, the remaining aspirate in the syringe
and needle were rinsed with 0.5 mL of normal saline
in micro-centrifuge tubes. This washout sample was
processed for Ct-FNA measurement. The Ct-FNA levels
were measured with immunoradiometric assay (IRMA)
(Diasource Immunoassays S.A, Belgium). A Ct-FNA level
higher than serum Ct level was considered positive rather
than an arbitrary cut-off level likewise earlier reports to
eliminate peripheral blood contamination.
2.4. Histopathological evaluation
After LN dissection, an expert thyroid-specific pathologist
(S.D.S) who is unaware of cytological and Ct-FNA results
made histological diagnoses. The histopathological
diagnosis of MTC was done with staining with
chromogranin, Ct, and/or CEA; and negatively stained
with thyroglobulin (Tg) and thyroid transcription factor 1
(TTF-1).
3. Statistical analysis
The Kolmogorov–Smirnov criterion was used for the
assessment of normality. Continuous variables were
expressed as a mean+standard deviation or median
(minimum and maximum). Discrete variables were
expressed as median with minimum and maximum
values instead of interquartile range to demonstrate
the heterogeneity of data. Categorical variables were
summarized as frequencies and percentages. The sensitivity,
specificity, diagnostic accuracy of FNAC and Ct-FNA
were calculated. Differences in sensitivity, specificity, and
diagnostic accuracy between Ct-FNA and FNAC were
evaluated by the Fisher’s exact test. The capacity of CtFNA and Ct-FNA/ sCt values in predicting metastasis in
LNs were analyzed using receiver operating characteristic
(ROC) curve analysis. When a significant cut-off value
was observed, the sensitivity, specificity values were
presented. While investigating the associations between
Ct-FNA and sCt levels, the correlation coefficients and
their significance were calculated using the Spearman test.
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Statistical analyses were performed using SPSS
statistical software (IBM Corp. Released in 2015. IBM
SPSS Statistics for Windows, Version 23.0. Armonk, NY:
IBM Corp.). A two-tailed p-value <0.05 was determined
as statistically significant.
4. Results
A total of 94 patients with the diagnosis of MTC were
included. There were 54 women and 40 men with a mean
age of 40.7 ± 17 years. A total of 61 cases (65%) were
sporadic while, 30 cases (32%) were multiple endocrine
neoplasia (MEN) type 2A and 3 (3%) cases were MEN 2B.
The median sCt level was 620 (54–9000) pg/mL, the
median CEA level was 9.4 (0.5–1958) ng/mL, and the mean
MTC lesion size in the thyroid was 26 ± 12.9 mm. Most
of the MTC histopathology was reported as multiple foci
at 27 patients (29%). Then, the MTC lesions were almost
evenly disturbed in the right (n = 18, 19%) and the left (n =
14, 15%) lobes, and less frequently as C-cell hyperplasia
(n = 4, 4%). The first operation and histopathological
evaluation of the 31 cases (n = 33%) were done in another
center.
Overall, 32 patients (F/M: 15/17) were recurrent
cases with cervical LN/distant metastasis for MTC. The
preoperative median sCt level in recurrent cases was 723
(54–9000) pg/mL and the preoperative CEA level was 9
(0.5–1958) ng/mL. FNAC was performed on 43, and CtFNAC was performed on 44 suspicious LNs. The median

largest diameter of the LNs was 9 (4–16) mm. The most
frequent localization of the regional recurrences of the
neck were found as left thyroid bed, right level III, and IV
of the lateral neck, respectively.
All 32 patients underwent surgery. Some patients
(n: 5) had predominant distant metastasis such as liver
(n: 2), lung (n: 2), or bone (n: 1) at the time of cervical
reoperation which were detected with neck/thorax/
abdomen computerized tomography (CT) and bone
scintigraphy. Tumor debulking was done for the neck due
to airway/esophageal obstruction (with multiple neck
metastasis of LNs) or alleviating the diarrheal syndrome.
The remaining patient who had highly elevated basal sCt
levels (n: 10), had undergone the same imaging procedure
but no involvement other than neck had been detected.
The distribution of the surgeries was as follows, tumor
debulking and LN dissection for 2 patients with a total of
5 LNs, only single neck LN metastasis for 18 patients for
18 LNs, and lymph node dissection for 12 patients with a
total of 21 LNs.
The postoperative pathological examination revealed
42 LN compatible with MTC and 2 benign (reactive)
LNs. FNAC findings for these LNs (Table 1) and the
histopathological distribution according to the FNAC
findings were described in Table 2. FNAC had a specificity
of 100% and a sensitivity of 85.3%.
The median Ct-FNA level of operated suspicious 44
LN was 1800 (151–9500) pg/mL. 42 LNs, all with positive

Table 1. Fine needle aspiration cytology findings of the suspicious lymph nodes.
Total

Hereditary

Sporadic

Nondiagnostic

5 (11.6%)

3 (7%)

2 (4.6%)

Benign

2 (4.6%)

1 (2.3%)

1 (2.3%)

Suspicious for malignancy

1 (2.2%)

1 (2.3%)

-

MTC

35 (81.3%)

13 (30%)

22 (51%)

MTC: Medullary Thyroid Cancer.
Table 2. Histopathological distribution of fine needle aspiration cytology (FNAC) and
calcitonin level in fine-needle aspirate washout fluid (Ct-FNA).
Histopathological results

FNAC results

Ct-FNA (pg/mL)

Benign LN

2 nondiagnostic

800 and 221

35 MTC

1800 (151–9500)

3 nondiagnostic

1800, 1800, 800

2 bening LN

2492 and 800

1 suspicious for malignancy

1700

MTC LN

LN: Lymph Node, MTC: Medullary Thyroid Cancer.
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Ct-FNA, were confirmed as MTC histopathologically. 2
of them with Ct-FNA results of 800 and 221 pg/mL were
diagnosed as benign (reactive) LNs.
Ct-FNA levels were same between sporadic 1507 (151–
9500) pg/mL and MEN 2A/2B cases 1800 (182–7154) pg/
mL. There was not a correlation between Ct-FNA and sCt
levels (p: 0.07, r: 0.34).
The diagnostic accuracies of FNAC versus Ct-FNA
were found 86% and 95.4%, respectively.
The median ratio of Ct-FNA/sCt levels for the entire
group, sporadic cases, MEN2A and MEN2B (n: 1) were
2.5 (1.06–28.1); 2.3 (1.06–23.6); 2.5 (1.3–28) and 6,
respectively. The tumor localizations of hereditary cases
were 11% left lobe and 89% multiple foci for MEN2A, and
100% multiple foci for MEN2B. These multiple foci were
predominantly made up of areas of C-cell hyperplasia.
ROC curve analysis showed an area under the curve
(AUC): 97%, (p: 0.001) for Ct-FNA, and the cut-off >638.5
pg/mL was determined according to the analysis with a
sensitivity of 80% and specificity of 94.9%. Based on the
curve, the AUC was 98% (p: 0.001) and the cut-off value of
Ct-FNA/sCt ratio was > 1.16 leading to 92.3% sensitivity
and 100% specificity.
5. Discussion
The primary aim of this study was to compare FNAC
and Ct-FNA results. For this purpose, there were studies
involving combined analysis of nodules and LNs together
previously. There was limited knowledge about the
comparison of FNAC and Ct-FNA in recurrent metastatic
LNs of MTC. In this retrospective study, we evaluated 43
FNAC and 44 Ct-FNA results only in recurrent suspicious
MTC LNs in a series of 32 patients for the first time. Our
major findings for metastatic LNs of MTC were cut-off
level for Ct-FNA was >638.5 pg/mL, Ct-FNA/sCt ratio
was >1.16, and diagnostic accuracy of Ct-FNA was higher
than FNAC (95.4% versus 86%).
As the survival varies by the extent of local disease,
the determination of the extent of the disease and the
diagnosis of the metastatic LNs with preoperative FNAC,
Ct-FNA procedures promise to achieve successful surgical
outcomes in recurrent cases of MTC.
Even though serum Ct is the most sensitive diagnostic
tool for MTC and has higher sensitivity compared to
cytology [16]; it does not point out the localization of the
primary tumor/metastases or recurrences in the neck after
initial surgery [1,17]. Also, it may be increased owing to
conditions such as renal failure, hypercalcemia, cigarette
smoking, neuroendocrine tumors, hypergastrinemia,
increased age, and interference with heterophilic
antibodies [18–20].
FNAC is the safe, accurate, and cost-effective approach
for the detection of metastatic LNs [21]. But the diagnosis
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of metastatic LNs of MTC depends on the knowledge and
experience of the cytopathologist because its diagnostic
accuracy is not as high as it is for PTC [8]. According to
a metaanalysis, the detection rate of FNAC in patients
with MTC was between 12.5% and 88.2%, with a pooled
estimate of 56.4% [20]. The major reasons for the low
detection rate of MTC with FNAC were inadequate
sampling, poor cellularity, nontypical cell shapes, and
unusual cytomorphologic presentations [22]. MTC was
also called a great mimicker owing to its many possible
microscopic patterns [19,23].
So, Ct-FNA is an ancillary diagnostic tool that can
provide useful information both for diagnosis and
localization of the tumor. After the first reports from Boi
et al. and Kudo et al., several reports showed that Ct-FNA
supported and increased the accuracy of cytopathologic
diagnosis[1,7,8,10,18,24]. Finally, the ATA MTC guideline
revised the suggestion as “Ct-FNAC should accurately
diagnose MTC and avoid false-negative or inconclusive/
nondiagnostic results from cytology [11].”
Likewise, in previous findings, we found higher
diagnostic accuracy (95.4% versus 86%) but lower
specificity (80% versus 100%) belonging to Ct-FNA for a
cut-off >638.5 than FNAC results. The diagnosis of MTC
can not be solely made with Ct-FNA, but be integrated
with FNAC. Two of the LNs were false positive with CtFNA and two of the LNs were false negative with FNAC, so
Ct-FNA is an additional procedure and can not substitute
FNAC. The combined usage of the two methods provides
better accuracy than any of them alone.
There was no correlation between Ct-FNA and sCt
levels. It was expected as a result of blood contamination,
but if there is no/little blood contamination or punction
(FNAC) is successful, the correlation between them could
not be obtained. Also, there is not any knowledge in the
literature showing a correlation between the size of the
lymph node and Ct-FNA. Moreover, there are differences
in the respective amounts of Tg and Ct within the
metastatic cells or released into the interstitial fluid during
needle aspiration.
The main limitation of the previous studies was
how to interpret the results of Ct-FNA correctly, as it is
an obligation to establish a cut-off value for Ct-FNA to
exclude the effect of peripheral blood contamination,
especially in patients with extremely high sCt. Giovanella
et al. and Trimboli et al. also stated the importance of
pre-analytic issues such as different Ct assays, the intermethod variability, and sample preparation for Ct-FNA
[25, 26]. We selected the ratio rather than an arbitrary cutoff to establish a better diagnostic accuracy as it had been
suggested for MTC nodules and parathyroid adenomas
[7, 27]. We found a Ct-FNA/sCt ratio greater than 1.16
with a sensitivity of 92.3 and specificity of 100%, which
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promises a more accurate diagnosis compared to fixed
cut-off ratios for metastatic LNs. The median ratio was
2.5 (1.06–28.1) for the entire group. The cut-off was much
lower than reported for differentiated thyroid cancers and
wash-out levels for thyroglobulin, but this was explained
due to differences in the respective amounts of Tg and Ct
within the metastatic cells or released into the interstitial
fluid during needle aspiration[1].
The limitations of our study were a small sample size
for recurrent LN metastasis because of the rarity of the
situation. Patients with high sCt levels and peripheral
contamination risk were other limitations. This study
had some strengths, including being the only study with
the highest number of lymph nodes with recurrent LNs,
and comparisons of FNAC, sCt, and Ct-FNA/sCt for LNs
especially in cases of markedly elevated sCt levels for the
first time.
In conclusion, Ct-FNAC, as an adjunct to FNAC,
should be performed as a preoperative surgical localization

technique to avoid false-negative MTC in all patients with
suspicious MTC. We suggest that the usage of a ratio rather
than a particular cut-off level will give more accurate
results, especially when markedly elevated sCt values are
measured.
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